Fig. (3).
Metabolomic analysis of GA-607-versus vehicle-treated EL4 tumors. GA-607 treatment caused an increase in FGAR, glucose, glutamine, and uridine 5′-diphospho-N-acetylglucosamine in the tumor and a decrease in succinate, aspartate, and nucleotide diphosphates.